Compare Avient Corporation (AVNT) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avient Corporation vs Mesoblast Limited — how do they compare? Avient Corporation trades at $35.82 (market cap $3.28B), while Mesoblast Limited trades at $17.61 (market cap $2.12B). The key difference: Avient Corporation is the larger of the two by market cap, and Avient Corporation pays a 3.07% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| AVNT | MESO | |
|---|---|---|
Market Cap | $3.28B | $2.12B |
Sector | Technology | Technology |
52-Week High | $43.28 | $20.96 |
52-Week Low | $27.48 | $10.96 |
Enterprise Value | $4.78B | $2.13B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Avient Corporation (AVNT) trades at $35.57, down 1.28% with a bearish technical signal. The company shows consistent earnings beats with Q1 2026 EPS of $0.83 exceeding expectations. Fundamentals reveal a P/E of 20.79 and net income margin of 4.81%, while cash flow trends improved from -$34M in 2025 to -$28M projected for 2026. Recent developments include new product launches and ClassNK approval for Dyneema DM20 fiber, supporting growth in renewable energy markets.
AVNT presents a mixed outlook with strong analyst support (60% buy ratings) offset by near-term technical weakness. The company's innovation pipeline and cost control measures provide upside potential, though macroeconomic headwinds and competitive pressures remain key risks. Earnings growth and successful market expansion of new technologies are critical catalysts for stock performance.
MESO trades at $16.22, up 5.05% today, with a bullish technical outlook from moving averages but mixed oscillators. The company shows strong gross margins of 80.52% but remains unprofitable with a net income margin of -144.33%. Recent news highlights commercial progress, including Ryoncil revenue of $36 million in Q4 2026 and pivotal Phase 3 trial milestones for chronic low back pain.
The outlook is cautiously optimistic, driven by FDA-approved Ryoncil's revenue growth and pipeline advancements, but high valuation (P/S 30.52) and persistent losses pose risks. Analyst consensus leans buy (45.46%), yet investors face volatility from clinical trial outcomes and cash burn concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Avient Corporation
Avient Corporation is a global leader in specialized and sustainable material solutions. Formed from the legacy of PolyOne and Clariant’s masterbatch business, it provides highly engineered polymer formulations, color systems, and advanced composites that enhance the performance and sustainability of products in industries like healthcare, defense, and consumer packaging.
Read more on AVNT →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
